Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

(Hasan was able to keep tabs on her body composition changes ... also seem to experience less muscle loss compared to those on semaglutide (the active ingredient in Ozempic), Dr. Neeland says.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...

Semaglutide and tirzepatide may be linked to ophthalmic complications due to rapid hyperglycemia correction, not drug toxicity. The study involved nine patients, with seven cases of nonarteritic ...

A new study shows that semaglutide can improve glucose levels for people with type 1 diabetes who use automated pumps, without increasing hypoglycemia. In this double-blinded randomized trial ...

Let's take a closer look at each of these medications. Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient ...